Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cefuroxime
Drug ID BADD_D00407
Description Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus.
Indications and Usage For the treatment of many different types of bacterial infections such as bronchitis, sinusitis, tonsillitis, ear infections, skin infections, gonorrhea, and urinary tract infections.
Marketing Status approved
ATC Code J01DC02; S01AA27
DrugBank ID DB01112
KEGG ID D00262
MeSH ID D002444
PubChem ID 41375
TTD Drug ID D0Y2IE
NDC Product Code 0143-9567; 0143-9569; 0143-9976; 0143-9568; 0143-9977; 0143-9979
UNII O1R9FJ93ED
Synonyms Cefuroxime | Cephuroxime | Zinacef | Ketocef
Chemical Information
Molecular Formula C16H16N4O8S
CAS Registry Number 55268-75-2
SMILES CON=C(C1=CC=CO1)C(=O)NC2C3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hepatic function abnormal09.01.02.001--Not Available
Hepatitis09.01.07.0040.000143%Not Available
Hepatitis toxic12.03.01.016; 09.01.07.0170.000143%Not Available
Hepatocellular injury09.01.07.0080.000143%Not Available
Hepatosplenomegaly09.01.05.002; 01.09.03.0010.000215%Not Available
Hyperaesthesia23.03.03.080; 17.02.06.0040.000143%Not Available
Hyperhidrosis23.02.03.004; 08.01.03.0280.001245%
Hyperkinesia17.01.02.008--Not Available
Hypersensitivity10.01.03.0030.004478%
Hypersensitivity vasculitis24.12.04.013; 23.06.02.005; 10.02.02.017; 01.01.04.0080.000215%Not Available
Hypoaesthesia23.03.03.081; 17.02.06.023--Not Available
Hypoalbuminaemia14.10.01.002; 09.01.02.0030.000286%
Hypocalcaemia14.04.01.0040.000215%
Hypokalaemia14.05.03.0020.000286%
Hypotension24.06.03.0020.002504%
Hypothermia12.05.03.001; 08.05.01.0030.000143%
Hypotonia neonatal18.04.01.006; 17.05.02.010; 15.05.04.0120.000143%Not Available
Immune system disorder10.02.01.001--Not Available
Influenza like illness08.01.03.010--
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Irritability08.01.03.011; 19.04.02.013--
Jarisch-Herxheimer reaction10.02.01.002--Not Available
Jaundice01.06.04.004; 23.03.03.030; 09.01.01.0040.000286%Not Available
Joint swelling15.01.02.004--Not Available
Laryngeal oedema22.04.02.001; 10.01.05.003; 23.04.01.0050.000143%
Leukocytosis01.02.01.0020.000358%
Leukopenia01.02.02.001--Not Available
Linear IgA disease23.03.01.015; 10.04.02.0060.000816%Not Available
Lip oedema07.05.04.004; 23.04.01.006; 10.01.05.0040.000286%Not Available
Lip swelling23.04.01.007; 10.01.05.005; 07.05.04.0050.000887%Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene